Each month, we'll highlight a few of the many trials enrolling volunteers. All past issues are available on the PFF Clinical Trials Blog. To view more trials for various forms of interstitial lung disease (ILD), visit the 🔍  PFF Clinical Trial Finder.

Let us know your feedback. Share your comments about this tool through the PF Drug Development Pipeline Survey. If you have information related to PF drugs in development to share, complete the PF Drug Development & Clinical Trials Form.

After Wyndel was diagnosed with ILD in 2018, he searched everywhere for hope, confronting the common narrative that individuals with ILD have a survival timeframe of three to five years. Motivated by his wife, children, and family, Wyndel chose to take part in three clinical trials. While the direct impact of these trials is difficult to quantify, he shared that his quality of life has improved by 100%. 

Wyndel offers encouragement to others navigating ILD, advising them to hold on, listen to their doctors, and welcome any opportunity to participate in research studies.

In June 2026, United Therapeutics announced that the United States Food and Drug Administration (FDA) granted premarket approval (PMA) for the LungFX device to perform centralized ex vivo lung perfusion (EVLP). EVLP is a procedure that keeps potential donor lungs alive outside of the body and allows for further assessment of the organs to determine if they are suitable for transplant. The additional time and assessment during EVLP can result in more lungs being accepted for transplantation. The LungFX device performs EVLP in a centralized location rather than at the transplant center creating broader access to EVLP technology.

The PMA included safety and effectiveness data supporting use of LungFX to perform EVLP in a centralized facility. The PMA was submitted by Lung Bioengineering Inc., a subsidiary of United Therapeutics.